Stock Analysis

Becton Dickinson Second Quarter 2025 Earnings: Misses Expectations

Advertisement

Becton Dickinson (NYSE:BDX) Second Quarter 2025 Results

Key Financial Results

  • Revenue: US$5.27b (up 4.5% from 2Q 2024).
  • Net income: US$308.0m (down 43% from 2Q 2024).
  • Profit margin: 5.8% (down from 11% in 2Q 2024).
  • EPS: US$1.07 (down from US$1.86 in 2Q 2024).
We've discovered 2 warning signs about Becton Dickinson. View them for free.
earnings-and-revenue-growth
NYSE:BDX Earnings and Revenue Growth May 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Becton Dickinson Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 33%.

Looking ahead, revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 18% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Becton Dickinson has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Becton Dickinson might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:BDX

Becton Dickinson

Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

Established dividend payer and slightly overvalued.

Advertisement

Weekly Picks

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8229.7% undervalued
51 users have followed this narrative
4 users have commented on this narrative
29 users have liked this narrative
WO
BMBL logo
woodworthfund on Bumble ·

Swiped Left by Wall Street: The BMBL Rebound Trade

Fair Value:US$961.3% undervalued
16 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
DUOL logo
WealthAP on Duolingo ·

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For

Fair Value:US$268.6434.2% undervalued
32 users have followed this narrative
5 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

CO
composite32
RMS logo
composite32 on Ramelius Resources ·

Ramelius: Beyond the definition of a safe haven in the current macroeconomic context.

Fair Value:AU$5.9230.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DS
NKE logo
DS2invest on NIKE ·

Nike: A Market Leader with Resilience and Long-Term Growth Potential

Fair Value:US$43.0153.3% overvalued
15 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
GOOGL logo
yiannisz on Alphabet ·

The Real Power Behind Alphabet’s Growth

Fair Value:US$192.5470.7% overvalued
23 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
70 users have followed this narrative
13 users have commented on this narrative
23 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25422.2% overvalued
73 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0226.9% undervalued
1029 users have followed this narrative
6 users have commented on this narrative
29 users have liked this narrative